Your fact-checks will appear here
The topic is about the weight regain after stopping GLP-1 receptor agonists, including the effects of the drug on appetite signaling and the physiological defenses triggered by weight loss.
Clinical trials and systematic reviews consistently show that stopping GLP‑1 receptor agonists such as semaglutide is commonly followed by clinically meaningful weight regain — often returning a large...
commonly leads to clinically meaningful weight regain within months to a year, though individual trajectories vary; randomized trials show much of the lost weight returns within 6–12 months and meta-a...
A small real‑world retrospective study of compounded once‑weekly combined with cyanocobalamin found an average weight loss of 4.11 kg (4.57% of starting weight) after three months, with most of the lo...
Clinical trials and systematic reviews consistently document clinically meaningful metabolic and weight rebound after stopping GLP‑1 receptor agonists, and while commentators and reviews urge “structu...
There are no clinical-trial documents in the supplied reporting that evaluate a product named “Gelatide,” so claims about its safety or efficacy cannot be corroborated from these sources; instead, the...